Patent protection for vygart ends when?

I can help, but I need one clarification: do you mean VYVGART (efgartigimod alfa) (the FcRn inhibitor used for conditions like gMG and CIDP), or a different “Vygart”?

Assuming you mean VYVGART (efgartigimod alfa):

• In the U.S., VYVGART’s key patent term generally runs until the mid‑to‑late 2030s, with the earliest exclusivity/patent expiration commonly cited around ~2034 (exact date depends on the specific patents and any extensions, such as patent term adjustments and eligibility for exclusivity).
• In the EU, similar exclusivity typically extends into the 2030s, again depending on the specific patent and regulatory exclusivities.

If you tell me country (US/EU/UK/etc.) and whether you mean VYVGART vs. VYVGART HYTRULO, I can give you the most accurate “ends when” answer for that market.